Global Uveitis Drugs Market 2019-2023

ブドウ膜炎薬の世界市場:小分子、生物製剤

◆タイトル:Global Uveitis Drugs Market 2019-2023
◆商品コード:IRTNTR31437
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年6月3日
◆ページ数:130
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:Americas, EMEA, APAC
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、ブドウ膜炎薬の世界市場について調べ、ブドウ膜炎薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ブドウ膜炎薬の市場規模をセグメンテーション別(製品別(小分子、生物製剤)、)と地域別(Americas, EMEA, APAC)に分けて算出しました。Technavio社はブドウ膜炎薬の世界市場規模が2019-2023期間中に年平均7%成長すると予測しています。
・サマリー
・レポートの範囲
・ブドウ膜炎薬の市場状況
・ブドウ膜炎薬の市場規模
・ブドウ膜炎薬の市場予測
・ブドウ膜炎薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(小分子、生物製剤)
・ブドウ膜炎薬の顧客状況
・主要地域別市場規模:Americas, EMEA, APAC
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

About this market

Several risk factors associated with uveitis had been a challenge during the diagnosis of eye disorders. Considering the complexities related to the diagnosis, vendors in the market are developing novel diagnostic tools and methods to treat patients with uveitis. Several companies are introducing AI-implemented medical devices to detect the level of diabetic retinopathy in patients with diabetes. Devices integrated with AI work autonomously and eliminate the need for specialists to make clinical decisions. Many such advancements have made the diagnosis of eye conditions easier. Ophthalmologists are leveraging such technical advantages and are providing the right treatment to patients. This is expected to drive the growth of the global uveitis drugs market size at a CAGR of around 7% during 2019-2023.

Market Overview

High prevalence of eye disorders and associated risk factors of uveitis

Uveitis is associated with several inflammatory diseases that cause swelling and destroy eye tissues. People with AIDS, rheumatic arthritis, multiple sclerosis, TB, and syphilis are more vulnerable to eye-related risk factors. The high prevalence of these diseases will have a positive impact on the market’s growth.

Availability of substitutes

Despite the availability of approved drugs, healthcare practitioners are adopting alternative treatment options such as surgery, laser treatment, and biopsy due to the side-effects associated with uveitis drugs. This is expected to hinder the growth of the global uveitis drugs market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the uveitis drugs market size during 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as AbbVie Inc. and Allergan Plc have intensified competition. Factors such as the recent advancements in the diagnosis of eye disorders and the high prevalence of eye disorders and associated risk factors of uveitis will provide significant growth opportunities for uveitis drug companies. AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Small molecules – Market size and forecast 2018-2023

Biologics – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Development of gene therapy

Special designations

Increasing popularity of combination therapies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AbbVie Inc.

Allergan Plc

Johnson & Johnson Services Inc.

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global ophthalmology drugs market

Exhibit 02: Segments of global ophthalmology drugs market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: Small molecules – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Some of the generic sponsors for corticosteroids

Exhibit 21: Different forms of corticosteroids

Exhibit 22: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 23: Biologics – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Some of the biologics used in uveitis

Exhibit 25: Cost of some biologics

Exhibit 26: Some of the approved biosimilars

Exhibit 27: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 28: Market opportunity by product

Exhibit 29: Customer landscape

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Prevalence of associated risk factors for uveitis

Exhibit 47: Drug development pipeline late stage molecules for uveitis

Exhibit 48: Adverse effects associated with available drugs

Exhibit 49: Impact of drivers and challenges

Exhibit 50: Vendor landscape

Exhibit 51: Landscape disruption

Exhibit 52: Vendors covered

Exhibit 53: Vendor classification

Exhibit 54: Market positioning of vendors

Exhibit 55: AbbVie Inc. – Vendor overview

Exhibit 56: AbbVie Inc. – Business segments

Exhibit 57: AbbVie Inc. – Organizational developments

Exhibit 58: AbbVie Inc. – Geographic focus

Exhibit 59: AbbVie Inc. – Key offerings

Exhibit 60: AbbVie Inc. – Key customers

Exhibit 61: Allergan Plc – Vendor overview

Exhibit 62: Allergan Plc – Business segments

Exhibit 63: Allergan Plc – Organizational developments

Exhibit 64: Allergan Plc – Geographic focus

Exhibit 65: Allergan Plc – Segment focus

Exhibit 66: Allergan Plc – Key offerings

Exhibit 67: Allergan Plc – Key customers

Exhibit 68: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 69: Johnson & Johnson Services, Inc. – Business segments

Exhibit 70: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 71: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 72: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 73: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 74: Johnson & Johnson Services, Inc. – Key customers

Exhibit 75: Novartis AG – Vendor overview

Exhibit 76: Novartis AG – Business segments

Exhibit 77: Novartis AG – Organizational developments

Exhibit 78: Novartis AG – Geographic focus

Exhibit 79: Novartis AG – Segment focus

Exhibit 80: Novartis AG – Key offerings

Exhibit 81: Novartis AG – Key customers

Exhibit 82: Pfizer Inc. – Vendor overview

Exhibit 83: Pfizer Inc. – Business segments

Exhibit 84: Pfizer Inc. – Organizational developments

Exhibit 85: Pfizer Inc. – Geographic focus

Exhibit 86: Pfizer Inc. – Segment focus

Exhibit 87: Pfizer Inc. – Key offerings

Exhibit 88: Pfizer Inc. – Key customers

Exhibit 89: Validation techniques employed for market sizing

Exhibit 90: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc.
Allergan Plc
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ブドウ膜炎薬の世界市場:小分子、生物製剤]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆